We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > olinvacimab

News List

PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020 prnasia
November 17, 2020
PharmAbcine Inc. announced that the company will present the final results of the Phase IIa clinical trial of Olinvacimab for rGBM (recurrent glioblastoma multiforme) patients at SNO (Society of Neuro-Oncology) 2020.
PharmAbcine Signs CMO Contract with Binex contractpharma
September 17, 2020
CDMO Binex to produce olinvacimab at its new 5,000L production line.
PharmAbcine, SLBio Enter NSCLC Research Pact contractpharma
August 04, 2020
To evaluate olinvacimab and C-005, a 3rd generation of EGFR inhibitor with superior brain-blood-barrier permeability in treating non-small cell lung cancer.